Evidence map›Paper›PMID 37226910›Full record

ArticleSubstance abuse

"I'm Clean and Sober, But Not Necessarily Free": Perceptions of Buprenorphine Among Patients in Long-Term Treatment.

Jessica J Wyse, Travis I Lovejoy, Adam J Gordon, Katherine Mackey, Anders Herreid-O'Neill, Benjamin J Morasco

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Substance abuse. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jessica J WyseCenter to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, USA.
Travis I LovejoyCenter to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, USA.
Adam J GordonInformatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
Katherine MackeyCenter to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, USA.
Anders Herreid-O'NeillOregon Rural Practice Network (ORPRN), Oregon Health & Science University, Portland, OR, USA.
Benjamin J MorascoCenter to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, OR, USA.
Oregon Health & Science University · USPortland State University · USUniversity of Utah · USVA Portland Health Care System · US

Funding

NW Center of Excellence & K12 in Patient Centered Learning Health Systems ScienceK12HS026370 · AHRQ · OREGON HEALTH & SCIENCE UNIVERSITY · PI EDEN, KAREN BEEKMAN, GUISE, JEANNE-MARIE · 2018 to 2022
$4.0M
AHRQ HHS K12 HS026370HSRD VA I50 HX001244HSRD VA IK2 HX003007
6 · The paper itself

Abstract

backgroundPatients receiving buprenorphine for the treatment of opioid use disorder (OUD) experience a roughly 50% reduction in mortality risk relative to those not receiving medication. Longer periods of treatment are also associated with improved clinical outcomes. Despite this, patients often express desires to discontinue treatment and some view taper as treatment success. Little is known about the beliefs and medication perspectives of patients engaged in long-term buprenorphine treatment that may underlie motivations to discontinue.

methodsThis study was conducted at the VA Portland Health Care System (2019-2020). Qualitative interviews were conducted with participants prescribed buprenorphine for ≥2 years. Coding and analysis were guided by directed qualitative content analysis.

resultsFourteen patients engaged in office-based buprenorphine treatment completed interviews. While patients expressed strong enthusiasm for buprenorphine as a medication, the majority expressed the desire to discontinue, including patients actively tapering. Motivations to discontinue fell into 4 categories. First, patients were troubled by perceived side effects of the medication, including effects on sleep, emotion, and memory. Second, patients expressed unhappiness with being "dependent" on buprenorphine, framed in opposition to personal strength/independence. Third, patients expressed stigmatized beliefs about buprenorphine, describing it as "illicit," and associated with past drug use. Finally, patients expressed fears about buprenorphine unknowns, including potential long-term health effects and interactions with medications required for surgery.

conclusionsDespite recognizing benefits, many patients engaged in long-term buprenorphine treatment express a desire to discontinue. Findings from this study may help clinicians anticipate patient concerns and can be used to inform shared decision-making conversations regarding buprenorphine treatment duration.

Indexed as

BuprenorphineLong-Term CareCommunicationFearHumansMotivationBuprenorphinebuprenorphineopioid-related disordersveterans

Identifiers

PMID37226910
PMCPMC11132627
OpenAlexW4367844638

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.